Other languages Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Delayed Nasdaq Other stock markets 02:35:36 2024-04-25 pm EDT			5-day change	1st Jan Change
2.75 ^USD	-1.61%		+4.96%	-13.52%

Mar. 07	Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	Jan. 04
Top Premarket Gainers	Nov. 08
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	Nov. 08
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Lumos Pharma, Inc. Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 inPGHD Met All Primary and Secondary Endpoints	Nov. 07
Lumos Pharma Says New Data Shows LUM-201 Restored Growth Hormone Secretion to Similar Levels in Normally Growing Children	23-09-26
Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting	23-09-26
Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting	23-09-14
Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Lumos Pharma Says Chief Medical Officer Leaving; Shares Drop	23-06-28
Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023	23-06-28
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar	23-06-21
Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting	23-05-08
Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01
Lumos Pharma, Inc. Completes Patient Enrollment in Two Phase 2 OraGrowth Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD	23-02-28
Lumos Pharma, Inc. Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral Lum-201 in Moderate Idiopathic PGHD	23-02-28
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency	22-11-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Other languages

Filters